What did @drjonesdc actually say?
The creator claims that AOD-9604, a synthetic peptide fragment derived from human growth hormone, can "mobilize body fat" in menopausal women and "bridge the gap" when insulin resistance makes fasting and low-carb diets difficult. The pitch is that menopause-related hormonal decline causes insulin resistance and fat accumulation, that typical dietary interventions like keto and intermittent fasting become harder to tolerate in menopause, and that AOD-9604 solves this by acting as a fat-mobilizing shortcut. The call to action is a text message inquiry, which is a direct commercial solicitation. Worth flagging upfront: "metapause" is not a medical term. The correct term is menopause, and using a non-standard word 11 times in a short video does not inspire clinical confidence.
Does the science back this up?
Mostly, no. AOD-9604 has a thin and mostly disappointing clinical record. The peptide was originally developed by Metabolic Pharmaceuticals as an obesity drug. Early animal studies were promising, but the human trials did not hold up. The pivotal Phase 2b/3 trials (Ng et al., 2000, International Journal of Obesity) found no statistically significant weight loss compared to placebo in obese adults. The drug failed to achieve FDA approval for obesity. There is zero peer-reviewed clinical evidence specifically in menopausal women. The insulin resistance framing is partially grounded in real physiology, but the leap to AOD-9604 as the fix is not supported by any published human trial data in this population.
What did they get wrong (or right)?
Credit where it is due: the claim that menopause is associated with increased insulin resistance and visceral fat accumulation is accurate and well-documented. Mauvais-Jarvis et al. (2013, Endocrine Reviews) confirmed that estrogen loss drives metabolic dysfunction, and that this creates real barriers to standard dietary interventions. The observation that fasting and low-carb protocols can be harder for some menopausal women due to cortisol dysregulation and sleep disruption is also a reasonable clinical observation, though it is overstated here as a blanket rule.
What they got wrong is the conclusion. The logic jumps from a real problem to an unsupported solution. Calling AOD-9604 "your ticket" to metabolic stability in menopause is not backed by any clinical trial in this population. The FDA reviewed this compound and did not approve it. Framing a failed pharmaceutical candidate as a wellness shortcut for menopausal women is misleading, regardless of the clinical credential attached to the name.
- Real: menopause increases insulin resistance and fat storage
- Real: some dietary strategies are harder to sustain in menopause
- Not real: AOD-9604 has demonstrated clinical efficacy for this in humans
- Not addressed: safety profile, regulatory status, or compounding considerations
What should you actually know?
AOD-9604 is not FDA-approved for any indication. It is available through compounding pharmacies in the US, which means it exists in a regulatory gray zone. The FDA has previously issued warning letters related to compounded AOD-9604 products. There are no published randomized controlled trials specifically examining AOD-9604 in menopausal women. The compound's proposed mechanism involves activating lipolysis through beta-3 adrenergic receptors, which sounds plausible in theory, but mechanism is not efficacy. Many compounds have logical mechanisms and still fail in trials, which is exactly what happened here.
If you are a menopausal woman struggling with weight and metabolic health, there are interventions with actual evidence behind them: resistance training (Bea et al., 2010, Menopause), hormone therapy in appropriate candidates (Stuenkel et al., 2015, Journal of Clinical Endocrinology and Metabolism), and structured dietary support. A DC credential, while legitimate for certain scopes of practice, does not confer prescriptive authority over peptide therapies in most US states, and that context is absent from this video entirely.